US equities
|
NVDA
$239.11
▲+2.21%
SPCX
$168.14
▲+5.78%
MU
$1,060.31
▼-1.36%
TSLA
$380.67
▲+2.72%
MSFT
$527.15
▲+1.86%
SNDK
$1,692.62
▼-1.59%
INTC
$116.52
▼-2.35%
META
$742.62
▲+2.00%
NVDA
$239.11
▲+2.21%
SPCX
$168.14
▲+5.78%
MU
$1,060.31
▼-1.36%
TSLA
$380.67
▲+2.72%
MSFT
$527.15
▲+1.86%
SNDK
$1,692.62
▼-1.59%
INTC
$116.52
▼-2.35%
META
$742.62
▲+2.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Bio-Thera Solutions, Ltd.
Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting
April 14, 2023
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
March 13, 2023
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
March 08, 2023
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors
March 06, 2023
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
China NMPA Approves Bio-Thera Solutions’ BAT1806, A Biosimilar to Actemra® (Tocilizumab)
January 16, 2023
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium
December 02, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)
November 01, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)
October 14, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces Details of Poster Presentation of a Highly Thermal Stable Recombinant Bivalent Nanoparticle Vaccine Containing Spikes of SARS-CoV-2 Omicron and Delta at Vaccine Summit 2022
October 11, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2
September 27, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors
August 02, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Advanced Solid Tumors
July 13, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors
May 09, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in a Phase 1 Study in Australia Evaluating BAT6026, an Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, an Anti-PD-1 Antibody
March 30, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT6021, an ADCC-enhanced Monoclonal Antibody Targeting TIGIT for the Treatment of Solid Tumors
January 24, 2022
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6026, a Monoclonal Antibody Targeting OX40
December 29, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT
December 29, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT2206, a Stelara® Biosimilar
October 15, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines
September 27, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)
September 08, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
August 27, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Tickers
HKMPY
Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)
July 15, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)
June 08, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
